MiMedx Group, Inc. (MDXG) P/E Ratio History
Deep ValueTrading at 13.1x · 15th percentile of 5-year range · Significant discount to historical valuation · Data 2014–2026
Loading P/E history...
P/E Ratio Analysis
As of July 8, 2026, MiMedx Group, Inc. (MDXG) trades at a price-to-earnings ratio of 13.1x, with a stock price of $4.20 and trailing twelve-month earnings per share of $0.21.
The current P/E is 88% below its 5-year average of 108.0x. Over the past five years, MDXG's P/E has ranged from a low of 9.4x to a high of 1518.8x, placing the current valuation at the 15th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.4x, MDXG trades at a 44% discount to its sector peers. The sector includes 231 companies with P/E ratios ranging from 0.0x to 198.8x.
Relative to the broader market, MDXG trades at a notable discount to the S&P 500 median P/E of 25.9x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our MDXG DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
MDXG Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
MDXG P/E vs Peers
Regenerative Medicine and Tissue Engineering peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $813M | 15.5 | 0.46Best | -35% | |
| $3B | 31.8 | 7.22 | -15% | |
| $59M | 14.0Lowest | - | +125%Best |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
MDXG Historical P/E Data (2014–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q1 | - | $3.95 | $0.20 | 19.3x | -89% |
| FY2025 Q4 | Dec 31 2025 | $6.77 | $0.32 | 20.9x | -88% |
| FY2025 Q3 | - | $6.98 | $0.27 | 25.5x | -85% |
| FY2025 Q2 | Jun 30 2025 | $6.11 | $0.22 | 27.9x | -84% |
| FY2025 Q1 | Mar 31 2025 | $7.60 | $0.27 | 27.7x | -84% |
| FY2024 Q4 | - | $9.62 | $0.29 | 33.6x | -80% |
| FY2024 Q3 | Sep 30 2024 | $5.91 | $0.59 | 10.1x | -94% |
| FY2024 Q2 | Jun 30 2024 | $6.93 | $0.59 | 11.8x | -93% |
| FY2024 Q1 | Mar 31 2024 | $7.70 | $0.46 | 16.6x | -90% |
| FY2023 Q4 | Dec 31 2023 | $8.77 | $0.36 | 24.5x | -86% |
| FY2023 Q3 | Sep 30 2023 | $7.29 | $0.00 | 1518.8x | +791% |
| FY2018 Q4 | Dec 31 2018 | $1.79 | $0.19 | 9.4x | -94% |
| FY2017 Q4 | Dec 31 2017 | $12.61 | $0.57 | 22.1x | -87% |
| FY2017 Q3 | Sep 30 2017 | $11.88 | $0.31 | 38.6x | -77% |
| FY2017 Q2 | Jun 30 2017 | $14.97 | $0.19 | 79.6x | -53% |
| FY2017 Q1 | Mar 31 2017 | $9.53 | $0.14 | 69.1x | -59% |
| FY2016 Q4 | Dec 31 2016 | $8.86 | $0.11 | 82.0x | -52% |
| FY2016 Q3 | Sep 30 2016 | $8.58 | $0.18 | 47.7x | -72% |
| FY2016 Q2 | - | $7.98 | $0.21 | 38.0x | -78% |
| FY2016 Q1 | - | $8.74 | $0.24 | 36.4x | -79% |
| FY2015 Q4 | - | $9.37 | $0.27 | 34.7x | -80% |
| FY2015 Q3 | Sep 30 2015 | $9.65 | $0.18 | 52.4x | -69% |
| FY2015 Q2 | - | $11.59 | $0.15 | 75.3x | -56% |
| FY2015 Q1 | - | $10.40 | $0.10 | 103.7x | -39% |
| FY2014 Q4 | Dec 31 2014 | $11.53 | $0.05 | 223.9x | +31% |
| FY2014 Q3 | - | $7.13 | $0.00 | 1782.5x | +946% |
Average P/E for displayed period: 170.5x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
12+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
MDXG — Frequently Asked Questions
Quick answers to the most common questions about buying MDXG stock.
What is MDXG's P/E ratio?
MiMedx Group, Inc. (MDXG) trailing twelve-month P/E ratio is 13.1x, based on TTM diluted EPS of $0.21. The 5-year average P/E is 108.0x and the historical range spans 9.4x to 1518.8x.
Is MDXG stock overvalued or undervalued?
MDXG trades at 13.1x P/E, below its 5-year average of 108.0x. At the 15th percentile of its historical range (9.4x–1518.8x), the stock is priced at a discount to its own history.
Is MDXG stock expensive?
No, MDXG is not expensive on a historical basis. The current P/E of 13.1x is below the 5-year average of 108.0x and sits at the 15th percentile of its valuation range.
What is MDXG's historical P/E range?
Over the past 5 years, MDXG's P/E ratio has ranged from 9.4x to 1518.8x, with a median of 27.9x and an average of 108.0x. The current P/E of 13.1x places the stock at the 15th percentile of this range. Full historical data spans 2014–2026.
How does MDXG's P/E compare to the S&P 500?
MDXG trades at 13.1x P/E versus the S&P 500 median of 25.9x. The 49% discount to the market suggests lower growth expectations or perceived higher risk.
How does MDXG's valuation compare to Healthcare peers?
MiMedx Group, Inc. P/E of 13.1x compares to the Healthcare sector median of 23.4x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is MDXG's PEG ratio?
MDXG PEG ratio is N/A, based on a P/E of 13.1x and EPS growth of 14.3%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is MDXG's earnings yield?
MDXG earnings yield is 7.62%, the inverse of its 13.1x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.